Dysregulation of the IL-23/Th17 pathway has been implicated in several autoimmune diseases, including SLE/LN, and inhibition of IL-23 and IL-17A with guselkumab and secukinumab, respectively, has demonstrated efficacy in improving the signs and symptoms of psoriasis [47] and PsA [48]. This evidence concerns the gene IL17A and systemic lupus erythematosus.